In Massachusetts, Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, announced an agreement with CoreBiome, a genomics platform company focused on accelerating microbiome innovation with expert genomics and big-data analytics, to provide high-scale and high-content microbiome data to increase the speed and productivity of Kaleido’s clinical development and discovery programs.
CoreBiome will conduct its proprietary BoosterShot shotgun sequencing service on tens of thousands of microbiome samples from Kaleido’s recently completed and ongoing clinical studies, in addition to samples from their proprietary screening platform. The resulting data combines with physiological data, metabolomics, and high-throughput screening assays to enable deep insights into how Kaleido’s chemistries invoke changes in microbiome function.
Geoffrey von Maltzahn, co-founder and President of Kaleido Biosciences said, “The BoosterShot platform enables us to better resolve individual bacterial species, and additionally it provides us with valuable information to decode functional signals.”